This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Real World Evidence
The information on this website is based on data from adult patients with ALK+ NSCLC treated with XALKORI®(crizotinib), produced in line with the XALKORI®(crizotinib) Summary of Product Characteristics for Great Britain. For XALKORI® (crizotinib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Progression-Free and Overall Survival in ALK+ NSCLC Patients Treated with Sequential XALKORI® and ceritinib
Observational retrospective analyses are designed to evaluate associations among variables and cannot establish causality. Observational retrospective analyses are not intended for direct comparison with clinical trials.
Study Design (Real World Evidence)
In this multicentre cohort, retrospective study, outcomes of 73 patients with ALK+ advanced non-small cell lung cancer (NSCLC) were analysed. Medical records were reviewed to determine progression-free survival (PFS) and overall survival (OS) following sequential treatment with XALKORI® and ceritinib. The median number of lines of treatment prior to XALKORI® was 1 (range: 0-8).1
The majority of patients (n=56) received a starting dose of 750mg once-daily XALKORI®.1
*Median number of lines of therapy prior to XALKORI® was 1 (range: 0-8). 27.4% of patients were treated with other therapies between XALKORI® and ceritinib.1
| Characteristic | All Patients (N=73) |
|---|---|
| Age at diagnosis, years | |
| Median | 50 |
| Range | 22-72 |
| Sex, n (%) | |
| Male | 38 (52%) |
| female | 35 (48%) |
| Ethnicity, n (%) | |
| Caucasian | 54 (74%) |
| Asian | 17 (23%) |
| Other | 2 (3%) |
| Smoking history, n (%) | |
| Never | 57 (78%) |
| Light (≤10 pack years) | 10 (14%) |
| Heavy (≥10 pack years) | 6 (8%) |
| Histology, n (%) | |
| Adenocarcinoma | 69 (95%) |
| Squamous | 3 (4%) |
| Adenosquamous | 1 (1%) |
| Stage at disgnosis, n (%) | |
| Stage I-II | 2 (3%) |
| Stage III-IV | 71 (97%) |
| Lines of therapy before crizotinib*, n (%) | |
| 0 | 10 (14%) |
| 1 | 32 (44%) |
| 2 | 16 (22%) |
| 3 | 7 (10%) |
| 4-8 | 8 (11%) |
| Brain metastases before crizotinib, n (%)† | |
| Present | 25 (35%) |
| Absent | 47 (65%) |
Adapted from Gainor JF, et al. Clin Cancer Res. 2015;21(12):2745-52.1
Data cutoff: June 2014
*All patients received XALKORI® before eventual treatment with ceritinib.1
†Neuroimaging was not available in 1 patient.1
Study Results (Real World Evidence)
Progression-Free Survival
Overall Survival
After a median follow-up of 53.2 months (data cutoff: June 2014), the median OS in the overall study population (n=73) was 49.4 months (95% CI: 35.5-63.1 months).1
OS from the time of metastatic NSCLC diagnosis for the overall study population*1
Overall survival from the first XALKORI® dose1
*10 patients received XALKORI® in first line; the remainder in the second-line or later. The median number of lines of therapy prior to XALKORI® was 1 (range 0–8).1
Adapted from Gainor JF, et al. Clin Cancer Res. 2015;21(12):2745-52.1
Data cutoff: June 2014
ALK: anaplastic lymphoma kinase, CI: confidence interval, mPFS: median progression-free survival NSCLC: non-small cell lung cancer, OS: overall survival, PFS: progression-free survival
References
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024